Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
K. Fujita (Kyoto, Japan), T. Imakita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors. 1037

Member's Comments

No comment yet.

Related content which might interest you: Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019 Serial interferon-gamma release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 CellCollector®: A novel method for the isolation of circulating tumor cells (CTC) in vivo and ex vivo in lung cancer patients during therapy Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Use of immune cell function assay in immune surveillance of lung transplant recipients: Correlations with clinical outcome and other immune assays Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019 In vitro and in vivo application of the GILUPI cell collector system for the isolation and characterization of circulating tumor cells (CTCs) in lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 The assessment of immune cells profile in blood and induced sputum in patients with COPD developing lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 674s Year: 2006 Influence of tumour cell lysate on state of lymphocytes‘ activation after DCs stimulation in lung cancer Source: Annual Congress 2008 - Airway cell biology and immunology Year: 2008 Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs Source: Eur Respir J 2009; 34: 702 Year: 2009 Serial interferon-gamma release assay in children with tuberculosis infection Source: Annual Congress 2010 - Tuberculosis in children Year: 2010 Extracts of lung cancer cells reveal antitumour antibodies in sera of patients with lung cancer Source: Eur Respir J 2003; 21: 342-346 Year: 2003 Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019 Year: 2019 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 From ineffective tumor immune response to immunomodulation in lung cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017 Involvement of Fas/FasL system in gemcitabine-induced lung cancer cell killing Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs? Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021